Ocrelizumab

• A Study Providing Continued Access to Treatment in Patients with a Neurological Disease Previously Enrolled in a Genentech and/or F. Hoffman… Not authorised
  2023-507633-21-00 Phase III 3 countries F. Hoffmann-La Roche AG
• A Study of Anti-CD19 CAR T-cell Therapy, in Subjects With Refractory Primary and Secondary Progressive Multiple Sclerosis Pending
  2024-511168-10-00 Phase II 4 countries Kyverna Therapeutics Inc.
• DESIRE MS: A prospective randomized non-inferiority trial comparing anti-CD20 maintenance versus De-Escalation Strategy In Relapsing-Remitti… Pending
  2024-513292-40-00 Phase III 1 country Centre Hospitalier Universitaire De Montpellier
• A Study Evaluating the Patient Perspective of the Physical Impact of Multiple Sclerosis and Providing Continued Access to Treatment in Patie… Recruiting
  2023-507633-21-01 Phase III 3 countries F. Hoffmann-La Roche AG
• A study to compare different doses of RO7268489 with a placebo (as add-on therapy to ocrelizumab) in people with multiple sclerosis that has… Recruiting
  2025-521636-10-00 Phase II 7 countries F. Hoffmann-La Roche AG
• A Study to Assess Bioequivalence of Two Subcutaneous Formulations of Ocrelizumab in Participants with Multiple Sclerosis Recruiting
  2024-517980-22-00 Phase II 5 countries F. Hoffmann-La Roche AG
• Efficacy and safety of remibrutinib after switching from ocrelizumab in participants living with relapsing multiple sclerosis, followed by o… Recruiting
  2023-509275-17-00 Phase III 10 countries Novartis Pharma AG
• The use of therapeutic monitoring of ocrelizumab serum concentrations for personalized pharmacotherapy of relapsing-remitting and primary pr… Recruiting
  2024-514549-12-00 Phase IV 1 country Fakultni Nemocnice Ostrava
• No Evidence Of Disease Activity After Autologous Haematopoietic Stem Cell Transplantation In Aggressive Multiple Sclerosis Recruiting
  2024-515470-26-00 Phase II 1 country Fondazione Italiana Sclerosi Multipla Ente Del Terzo Settore/et S
• For patients with active multiple sclerosis, impact of annual versus semi-annual infusions of ocrelizumab after 2 years of initial treatment… Recruiting
  2023-505420-62-00 Phase III 1 country Hopital Fondation Adolphe De Rothschild
• A Randomized, Double-blind, Parallel-group Study to Compare Pharmacokinetics, Pharmacodynamics, Clinical Effects, and Safety between ABP 692… Ended
  2024-512914-16-00 Phase III 15 countries Amgen Inc.
• A Double-blind, Randomized, Active-controlled, Parallel-group, Phase 1/3 study to Compare Efficacy, Pharmacokinetics, Pharmacodynamics and S… Ended
  2022-501622-37-00 Phase III 6 countries Celltrion Inc.
• Metformin add-on clinical study in multiple sclerosis to evaluate brain remyelination and neurodegeneration: a phase IIb triple-blind placeb… Ended
  2023-503190-38-00 Phase II 1 country Antwerp University Hospital
• TRIO: A prospective randomized Trial of non-inferiority comparing RItuximab versus Ocrelizumab in relapsing-remitting multiple sclerosis. Ended
  2022-501027-25-01 Phase III/IV 1 country CHU De Rennes
• Noisy Rebels; Non-inferiority study of rituximab compared to ocrelizumab in relapsing MS Ended
  2022-502664-21-00 Phase IV 1 country Amsterdam UMC
• A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Ocrelizumab In Patients with Multiple Sclerosis Ended
  2023-505974-14-00 Phase III 20 countries F. Hoffmann-La Roche AG
• Personalized dosing of ocrelizumab in MS Ended
  2024-513193-22-00 Phase III/IV 1 country Amsterdam UMC Stichting
• A Study to Evaluate Safety and Efficacy of Ocrelizumab in Comparison with Fingolimod in Children and Adolescents with Relapsing-Remitting Mu… Ended
  2023-506516-40-00 Phase III 17 countries F. Hoffmann-La Roche AG
• Non-inferiority study of ocrelizumab and rituximab in active multiple sclerosis Ended
  2024-514287-84-00 Phase III 1 country Rigshospitalet
• A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of a Higher Dose of Ocrelizumab in Adults With Primary Progressive Multiple Sc… Ended
  2023-506515-18-00 Phase III 11 countries F. Hoffmann-La Roche AG
• Ocrelizumab VErsus Rituximab off-Label at the Onset of Relapsing MS Disease (OVERLORD-MS) Ended
  2024-510716-71-00 Phase III 2 countries Helse Bergen HF
• A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of a Higher Dose of Ocrelizumab in Adults with Relapsing Multiple Sclerosis Ended
  2023-506467-34-00 Phase III 10 countries F. Hoffmann-La Roche AG
• A Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Effects of Ocrelizumab in Children and Adolescents with Rela… Ended
  2023-507313-94-00 Phase II 2 countries F. Hoffmann-La Roche AG
• A Study to Evaluate the Efficacy and Safety of Ocrelizumab in Adults with Primary Progressive Multiple Sclerosis Ended
  2023-505980-36-00 Phase III 9 countries F. Hoffmann-La Roche AG

Showing 1–24 of 30 trials